BACKGROUND: In recent years, @entity205 (CsA) has emerged as a promising therapy to limit @entity741 , presumably by inhibiting the opening of the mitochondrial permeability transition pore. Results from different large animal models are conflicting, however, with failure to prove beneficial effects of 10 mg/kg CsA administered at reperfusion. Recently, a small clinical study using a bolus of 2.5 mg/kg CsA showed promising but not unequivocal results. The aim of the present study was to estimate the magnitude of a possible @entity1188 reduction with the use of the latter regimen in a closed-chest porcine model for @entity63 and reperfusion. Materials and METHODS: @entity1707 underwent catheterization with balloon occlusion of the left descending coronary artery for 40 minutes, followed by reperfusion for 4 hours. They were randomized to receive an intravenous bolus 7 minutes before reperfusion of either 2.5 mg/kg CsA (n = 12) or saline (control, n = 11). Hearts were stained to quantify area at risk and @entity1188 size. RESULTS: Throughout the experiment, there were no differences between the groups in baseline characteristics or hemodynamic variables. CsA treatment did not reduce @entity1188 size as a proportion of area at risk compared with control (51%    6% and 54%    6%, respectively, P = .75). CONCLUSION: In a closed-chest porcine model for @entity741 and reperfusion injury, 2.5 mg/kg @entity870 administered before reperfusion did not reduce @entity1188 size.

@entity205 , 2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of XXXX and reperfusion.

@entity1707 :: ('9823', 'Species') :: ['Pigs'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity870 :: ('CHEBI:55379', 'Chemical') :: ['CsA'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine A'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemic-reperfusion injury', 'myocardial ischemia']
@entity63 :: (MESH:D007511,Disease) :: ['ischemia']
